Description:FORM 2
THE PATENT ACT 1970
(39 of 1970)
&
THE PATENTS RULES, 2003
COMPLETE SPECIFICATION
(See Section 10, and rule 13)

NEUROMODULATION THERAPY TINNITUS RELIEF DEVICE FOR
TINNITUS PROBLEM

APPLICANT(S)
Name: Drspectra Wellness Pvt. Ltd.
Nationality: Indian
Address: F-104 , Express Green, Sector-1,
New Mahagun Mall , Vaishali, Ghaziabad,
Uttar Pradesh -201010

The following specification particularly describes the invention and the manner in which it is to be performed:

BACKGROUND
Field of Invention
[001] Embodiments of the present invention relate to a portable device designed to assist with hearing disabilities, and more particularly relates to a neuromodulation device for alleviating conditions such as tinnitus by influencing neural activity related to auditory functions.
Description of Related Art
[002] Tinnitus is a complex hearing syndrome commonly caused by prolonged exposure to intense and loud noises. Such noise sources include loud machinery, music, or any other sounds that are received by the ear in a synchronized manner. Additionally, tinnitus can result from acoustic trauma, such as a sudden exposure to a loud bang or unexpected exposure to a loud sound. Individuals suffering from tinnitus typically experience an auditory perception of buzzing, ringing, or a siren-like noise in their ears, even though no external sound is present. This phenomenon occurs because the brain of the tinnitus sufferer mistakenly interprets or generates these noises through the auditory cortex, leading to a persistent and often distressing auditory experience.
[003] An impact of tinnitus extends beyond the auditory symptoms and leads to significant indirect consequences. As per a study, globally, tinnitus-related hearing loss contributes to an estimated annual economic loss of approximately USD 980 billion. The condition affects individuals' employment and financial stability, impedes daily activities, and disrupts driving abilities. Additionally, tinnitus restricts social engagement and hampers communication, which often leads to feelings of grief, depression, and isolation, and further diminishes a quality of life for those affected.
[004] Although there are various commercial devices and methods available for the management of tinnitus syndrome, a comprehensive approach to handling it is lacking. The availability and awareness of effective options remain insufficient. Existing devices and methods often fail to provide a wide-reaching solution or fail to address needs of a diverse patient population. This gap in accessibility and awareness highlights the need for improved and more widely accessible options.
[005] Current solutions for tinnitus involve stimulating other parts of the body, such as the tongue, earlobes, or other regions. However, these methods are frequently inconvenient, uncomfortable, and impractical for daily use. The process of administering stimulation can be slow and painful, and such solutions are typically unsuitable for use in public settings or while the patient is mobile. Effective therapy often requires the patient to be stationary and in a private setting that limits practicality and adherence to therapy. Despite the available solutions, still there is a lack of a more convenient, portable, and comfortable solution that can allow an effective supervision of tinnitus in various settings and during daily activities.
[006] A commercially available product ‘Lenire’ by ‘Neuromod Devices’ treats tinnitus syndrome by playing sound over a pair of Bluetooth headphones. The sound played on the Bluetooth headphones reduces the perception of tinnitus noise. Additionally, the product uses electrical stimulations through a tongue for the treatment of tinnitus syndrome. However, utilizing the tongue as a means for provision of stimulation restricts useability of the product from public spaces and a user must be present in a private accommodation for receiving the treatment by the product.
[007] Another commercially available hearing aid device by ‘Neuromonics’ treats the tinnitus syndrome by playing customised music which further has to be listened by the user. Moreover, the customized music must be consumed using a pair of earphones for a period of two continuous hours per day. However, the utilization of the device for the period of two continuous hours per day is not comfortable for many of demography. Additionally, the music treatment has not proved effective in curing the tinnitus syndrome for long term benefits.
[008] There is thus a need for an improved and advanced neuromodulation device that can administer the aforementioned limitations in a more efficient manner.
SUMMARY
[009] Embodiments in accordance with the present invention provide a neuromodulation device. The device comprising: an input unit adapted to receive inputs from a physical auditory test conducted on a patient. The device further comprising: a storage unit adapted to store the received inputs. The device further comprising: a processor connected to the storage unit. The processor is configured to: analyze the received inputs of the physical auditory test stored in the storage unit, wherein the analysis of the received inputs provide a percentage of a Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz), a percentage of a Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz), and a percentage of a Hyperacusis Severity Test (HH1) value at 8 Kilohertz (kHz), or a combination thereof; extract a set of variables (s1, s2, and s3) from the analyzed inputs; calculate a total duration (T) of a wave pattern by summing the extracted set of variables (s1, s2, and s3); compute a first intensity (A), a second intensity (B), and a central frequency (fc) of the wave pattern from the analyzed inputs; parse the total duration (T), the first intensity (A), the second intensity (B), and the central frequency (fc) of the wave pattern through an equation for generating an audible wave pattern; calculate a neuromodulation acoustic energy by multiplying the total duration (T) of the wave pattern with the first intensity (A), and the second intensity (B) of the wave pattern; and actuate an output unit to emit the generated wave pattern with the calculated neuromodulation acoustic energy.
[0010] Embodiments in accordance with the present invention further provide a method for operating a neuromodulation device. The method comprising steps of: analyzing received inputs of a physical auditory test stored in a storage unit, wherein the analysis of the received inputs provide a percentage of a Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz), a percentage of a Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz), and a percentage of a Hyperacusis Severity Test (HH1) value at 8 Kilohertz (kHz), or a combination thereof; extracting a set of variables (s1, s2, and s3) from the analyzed inputs; calculating a total duration (T) of a wave pattern by summing the extracted set of variables (s1, s2, and s3); computing a first intensity (A), a second intensity (B), and a central frequency (fc) of the wave pattern from the analyzed inputs; parsing the total duration (T), the first intensity (A), the second intensity (B), and the central frequency (fc) of the wave pattern through an equation for generating an audible wave pattern; calculating a neuromodulation acoustic energy by multiplying the total duration (T) of the wave pattern with the first intensity (A), and the second intensity (B) of the wave pattern; and actuating an output unit to emit the generated audible wave pattern with the calculated neuromodulation acoustic energy.
[0011] Embodiments of the present invention may provide a number of advantages depending on their particular configuration. First, embodiments of the present application may provide a neuromodulation device.
[0012] Next, embodiments of the present application may provide a neuromodulation device that alleviates tinnitus syndrome.
[0013] Next, embodiments of the present application may provide a neuromodulation device that alleviates hyperacusis syndrome.
[0014] Next, embodiments of the present application may provide a neuromodulation device that alleviates dizziness.
[0015] Next, embodiments of the present application may provide a neuromodulation device that manages concentration problems.
[0016] Next, embodiments of the present application may provide a neuromodulation device that improves hearing clarity.
[0017] Next, embodiments of the present application may provide a neuromodulation device that alleviates and improves light headiness and fainting feelings.
[0018] Next, embodiments of the present application may provide a neuromodulation device that is designed to be used for 15 minutes to 20 minutes, 3 times a day for a period of 8 months to 12 months.
[0019] Next, embodiments of the present application may provide a neuromodulation device that is a lightweight, portable, and clinically validated therapeutic device.
[0020] Next, embodiments of the present application may provide a neuromodulation device that is affordable and does not provide any side effects to a patient.
[0021] These and other advantages will be apparent from the present application of the embodiments described herein.
[0022] The preceding is a simplified summary to provide an understanding of some embodiments of the present invention. This summary is neither an extensive nor exhaustive overview of the present invention and its various embodiments. The summary presents selected concepts of the embodiments of the present invention in a simplified form as an introduction to the more detailed description presented below. As will be appreciated, other embodiments of the present invention are possible utilizing, alone or in combination, one or more of the features set forth above or described in detail below.
BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The above and still further features and advantages of embodiments of the present invention will become apparent upon consideration of the following detailed description of embodiments thereof, especially when taken in conjunction with the accompanying drawings, and wherein:
[0024] FIG. 1A illustrates a neuromodulation device, according to an embodiment of the present invention;
[0025] FIG. 1B illustrates an exploded view of the neuromodulation device, according to an embodiment of the present invention;
[0026] FIG. 1C illustrates an exemplary circuit diagram depicting a connection between a processor and an output unit of the neuromodulation device, according to an embodiment of the present invention;
[0027] FIG. 2 illustrates a block diagram of a processor of the neuromodulation device, according to an embodiment of the present invention;
[0028] FIG. 3A illustrates a first graph illustrating a gender-based distribution of participants participating in a clinical experimentation for the neuromodulation device, according to an embodiment of the present invention;
[0029] FIG. 3B illustrates a second graph illustrating a hearing loss in a right ear of the participants participating in the clinical experimentation for the neuromodulation device, according to an embodiment of the present invention;
[0030] FIG. 3C illustrates a third graph illustrating a hearing loss in a left ear of the participants participating in the clinical experimentation for the neuromodulation device, according to an embodiment of the present invention;
[0031] FIG. 3D illustrates a fourth graph illustrating a mean of ages and improvements in the participants participating in the clinical experimentation for the neuromodulation device, according to an embodiment of the present invention;
[0032] FIG. 3E illustrates a fifth graph illustrating a mean of a Tinnitus Severity Index (THI) in the participants participating in the clinical experimentation for the neuromodulation device, according to an embodiment of the present invention;
[0033] FIG. 3F illustrates a sixth graph illustrating a mean of a Hyperacusis Severity Index (HYP) in the participants participating in the clinical experimentation for the neuromodulation device, according to an embodiment of the present invention;
[0034] FIG. 3G illustrates a seventh graph illustrating a mean of a Dizziness Severity Index (DHI) in the participants participating in the clinical experimentation for the neuromodulation device, according to an embodiment of the present invention; and
[0035] FIG. 4 depicts a flowchart of a method for operating the neuromodulation device to manage hearing-related conditions, according to an embodiment of the present invention.
[0036] The headings used herein are for organizational purposes only and are not meant to be used to limit the scope of the description or the claims. As used throughout this application, the word "may" is used in a permissive sense (i.e., meaning having the potential to), rather than the mandatory sense (i.e., meaning must). Similarly, the words “include”, “including”, and “includes” mean including but not limited to. To facilitate understanding, like reference numerals have been used, where possible, to designate like elements common to the figures. Optional portions of the figures may be illustrated using dashed or dotted lines, unless the context of usage indicates otherwise.
DETAILED DESCRIPTION
[0037] The following description includes the preferred best mode of one embodiment of the present invention. It will be clear from this description of the invention that the invention is not limited to these illustrated embodiments but that the invention also includes a variety of modifications and embodiments thereto. Therefore, the present description should be seen as illustrative and not limiting. While the invention is susceptible to various modifications and alternative constructions, it should be understood, that there is no intention to limit the invention to the specific form disclosed, but, on the contrary, the invention is to cover all modifications, alternative constructions, and equivalents falling within the scope of the invention as defined in the claims.
[0038] In any embodiment described herein, the open-ended terms "comprising", "comprises”, and the like (which are synonymous with "including", "having” and "characterized by") may be replaced by the respective partially closed phrases "consisting essentially of", “consists essentially of", and the like or the respective closed phrases "consisting of", "consists of”, the like.
[0039] As used herein, the singular forms “a”, “an”, and “the” designate both the singular and the plural, unless expressly stated to designate the singular only.
[0040] FIG. 1A illustrates a neuromodulation device 100 (hereinafter referred to as the device 100), according to an embodiment of the present invention. In an embodiment of the present invention, the device 100 may be designed to alleviate tinnitus symptoms in a patient. In an embodiment of the present invention, the device 100 may further be designed to reduce a distress, a panic, an anxiety, and other conditions that may be associated with the tinnitus symptoms. In an embodiment of the present invention, the device 100 may be configured to analyse an auditory test data of the patient and may generate an audible wave pattern of a specific frequency based on a severity of the tinnitus symptoms. In an embodiment of the present invention, the device 100 may incorporate advanced modulation techniques to enhance a comfort level of the patient by providing a precise and patient-specific solution for managing the tinnitus in the patient.
[0041] In an embodiment of the present invention, the device 100 may initially be configured by a medical practitioner as per the auditory test data of the patient. The device 100 may enable the medical practitioner to monitor an improvement in the patient, in an embodiment of the present invention. According to embodiments of the present invention, the medical practitioner may be, but not limited to, a doctor, a nurse, a caretaker, a therapist, an ear-nose-throat (ENT) specialist, a warden, and so forth.
[0042] In an embodiment of the present invention, the device 100 may comprise a housing 102. In an embodiment of the present invention, the housing 102 of the device 100 may be designed to be portable and to be easily carried by the patient. In a preferred embodiment of the present invention, the housing 102 may be having dimensions such as 106 millimetres (mm) in height, 59 millimetres (mm) in width, and 23 millimetres (mm) in length. The housing 102 may weigh around 300 grams (g), in an embodiment of the present invention. Embodiments of the present invention are intended to include or otherwise cover any dimensions and weight for the housing 102 of the device 100, including known, related art, and/or later developed technologies.
[0043] In an embodiment of the present invention, the housing 102 may comprise a top panel 104a, a bottom panel 104b, a left side panel 104c, and a right side panel 104d. According to embodiments of the present invention, the housing 102 may be constructed of any material such as, but not limited to, a metallic material, a glass material, a plastic material, and so forth.
[0044] FIG. 1B illustrates an exploded view of the device 100, according to an embodiment of the present invention. In an embodiment of the present invention, the housing 102 may encapsulate, non-limiting functional components of the device 100. The components of the device 100 may be an input unit 106, a storage unit 108, a processor 110, an output unit 112, a display unit 114, a battery 116, and a charging port 118. In an embodiment of the present invention, the device 100 may comprise a timer (not shown) that may be adjusted and set either locally by the patient or remotely by the medical practitioner.
[0045] The input unit 106 may be located on a front side of the device 100. The input unit 106 may be, but not limited to, a keyboard, a knob, a joystick, and so forth. In a preferred embodiment of the present invention, the input unit 106 may be a membrane keypad. In an embodiment of the present invention, the membrane keypad may be a 2-millimeter (mm) membrane keypad. Embodiments of the present invention are intended to include or otherwise cover any type of the input unit 106, including known, related art, and/or later developed technologies.
[0046] In an embodiment of the present invention, the input unit 106 may be adapted to receive inputs from the patient and/or the audiologist. The inputs received by the input unit 106 may be, but not limited to, a type of tinnitus, an intensity of tinnitus, a severity of tinnitus, a date and time of conduction of the physical auditory test, a text remark from the audiologist conducting the physical auditory test.
[0047] In another embodiment of the present invention, the inputs provided by the patient to the input unit 106 may be selected from a tinnitus profile of the patient that may be created by using a computer device (not shown) from an auditory test data report that is obtained based on the physical auditory examination. In an embodiment of the present invention, the physical auditory test may be conducted by an audiologist using means such as, but not limited to, a hearing apparatus, an audio box, a music player, a mobile phone with pre-stored tones and beeps, a jukebox, the device 100 and so forth. Embodiments of the present invention are intended to include or otherwise cover any means for conducting the physical auditory test on the patient, including known, related art, and/or later developed technologies.
[0048] In an embodiment of the present invention, the audiologist may conduct the physical auditory test by exposing the patient to a series of volumetrically incrementing tones and beeps across a frequency spectrum. The patient reports whether the exposed tones and beeps are audible by responding in a verbal and/or written ‘YES’ to the audiologist. In another embodiment of the present invention, the patient may report an inaudibility of the exposed tones and the beeps by responding in a verbal and/or written ‘NO’ to the audiologist.
[0049] In an embodiment of the present invention, the storage unit 108 may be adapted to store the received inputs. The storage unit 108 may be a non-transitory storage medium. In an embodiment of the present invention, non-limiting examples of the storage unit 108 may be a Read Only Memory (ROM), a Random-Access Memory (RAM), an Erasable Programmable Read Only Memory (EPROM), an Electrically Erasable Programmable Read Only Memory (EEPROM), a hard drive, a removable media drive for handling memory cards, and so forth. Embodiments of the present invention are intended to include or otherwise cover any type of the storage unit 108, including known, related art, and/or later developed technologies.
[0050] In an embodiment of the present invention, the processor 110 may be connected to the input unit 106 and the output unit 112. Further, the storage unit 108 may be communicatively coupled with the processor 110. The processor 110 may be configured to the inputs from the physical auditory test conducted on the patient. Further, the processor 110 may be configured to generate the wave pattern corresponding to the tinnitus profile of a patient. The generated audible wave pattern may when exposed to the ear of the patient tend to cure the tinnitus syndrome.
[0051] In an embodiment of the present invention, the processor 110 may be configured to store the generated audible wave pattern in the storage unit 108. The storage unit 108 may be adapted to store the audible wave pattern generated by the processor 110. The storing of the audible wave pattern in the storage unit 108 may enable the patient to conduct tinnitus therapy at their convenience. Moreover, storage of the audible wave pattern in the storage unit 108 may ensure the emission of correct and precise audible wave patterns every time the patient conducts the tinnitus therapy. Further, the storage of the audible wave pattern in the storage unit 108 may prevent the patient from conducting the physical auditory test every time the patient wants to conduct the tinnitus therapy.
[0052] The processor 110 may further be configured to execute computer-executable instructions to generate an output relating to the device 100. The processor 110 may be, but not limited to, a Programmable Logic Control (PLC) unit, a microprocessor, a development board, and so forth. Embodiments of the present invention are intended to include or otherwise cover any type of the processor 110 including known, related art, and/or later developed technologies. In an embodiment of the present invention, the processor 110 may further be explained in detail in conjunction with FIG. 2.
[0053] In an embodiment of the present invention, the output unit 112 may be adapted to emit the wave pattern generated by the processor 110. In a preferred embodiment of the present invention, the output unit 112 may be located on the bottom panel 104b of the device 100. In another embodiment of the present invention, the output unit 112 may be located on the top panel 104a of the device 100. In yet another embodiment of the present invention, the output unit 112 may be located either on the left side panel 104c, or on the right side panel 104d of the device 100. Embodiments of the present invention are intended to include or otherwise cover any location of the output unit 112 on the device 100, including known, related art, and/or later developed technologies.
[0054] In an embodiment of the present invention, the output unit 112 may be adapted to be paired with a listening peripheral (not shown). The listening peripheral may be adapted to carry the wave pattern in an ear canal of the patient. In an embodiment of the present invention, the listening peripheral operating in a range from 90 decibels (dB) to 105 decibels (dB) may be compatible with the output unit 112 of the device 100. In an embodiment of the present invention, the listening peripheral may be of a wired medium. In another embodiment of the present invention, the listening peripheral may be a wireless medium operating on a Bluetooth protocol. According to embodiments of the present invention, the listening peripheral may be, but not limited to, earphones, headphones, and so forth. Embodiments of the present invention are intended to include or otherwise cover any type of the listening peripheral, including known, related art, and/or later developed technologies.
[0055] The audible wave pattern emitted by the output unit 112 may comprise a sine component of the wave pattern, a cosine component of the wave pattern, a sine and cosine component of the wave pattern, and so forth. In an embodiment of the present invention, the device 100 may operate in a unilateral mode. In such an embodiment of the present invention, the output unit 112 of the device 100 may be configured to emit either the sine component of the generated wave pattern or the cosine component of the generated wave pattern. In another embodiment of the present invention, the device 100 may operate in a bilateral mode. In such an embodiment of the present invention, the output unit 112 of the device 100 may be configured to emit both the sine component and the cosine component of the generated wave pattern. In yet another embodiment of the present invention, the output unit 112 of the device 100 may be configured to support both the unilateral mode and the bilateral mode, allowing the patient to select a desired mode for operation.
[0056] In an embodiment of the present invention, the output unit 112 may be, but not limited to, a mono channel, a stereo channel, and so forth. Embodiments of the present invention are intended to include or otherwise cover any channel of the output unit 112, including known, related art, and/or later developed technologies. In an embodiment of the present invention, the device 100 may be configured to operate in a range from 2 channels per filter to 32 channels per filter. Thus, the output unit 112 of the device 100 may be capable of handling two or more wave patterns simultaneously. In such an embodiment of the present invention, the device 100 may utilize a frequency-dependent amplifier (not shown) in a passive circuit (not shown) to remove unwanted frequencies from the wave pattern. In an embodiment of the present invention, the device 100 may be operated across a frequency range from 1 Hertz (Hz) to 8000 Hertz (Hz), with support for frequencies that may initiate from 4 Kilohertz (kHz).
[0057] In an embodiment of the present invention, the output unit 112 of the device 100 may emit the generated wave pattern that may be of an intensity ranging from 10 decibels (dB) to 50 decibels (dB). Embodiments of the present invention are intended to include or otherwise cover any intensity range provided by the device 100. In an embodiment of the present invention, a frequency output of the device 100 may be in a range from 100 Hertz (Hz) to 20 Kilohertz (KHz). Embodiments of the present invention are intended to include or otherwise cover any frequency output of the device 100. In an embodiment of the present invention, a step size of change of the intensity of the device 100 may be in a range from 2 decibels (dB) to 5 decibels (dB). According to embodiments of the present invention, the step size of change of the intensity of the device 100 may be a least count of the intensity that may be changed by the device 100 when instructed to change the intensity by one unit. Embodiments of the present invention are intended to include or otherwise cover any step size of change of the intensity of the device 100. In an embodiment of the present invention, the device 100 may operate in a frequency range from 0.1 Kilohertz (KHz) to 16 Kilohertz (KHz). Embodiments of the present invention are intended to include or otherwise cover any operational frequency range of the device 100.
[0058] In an embodiment of the present invention, a tone accuracy of the wave pattern generated by the device 100 may be in a range from 0.1 percentage (%) to 0.3 percentage (%). In a preferred embodiment of the present invention, the tone accuracy of the device 100 may be within 0.2%. Embodiments of the present invention are intended to include or otherwise cover any percentage of tone accuracy of the device 100. According to embodiments of the present invention, the tone accuracy of the device 100 refers to the precision with which the device 100 emits tones as instructed. For example, if the device 100 is configured to emit the wave pattern at 308 Kilohertz (kHz) with the intensity of 10 decibels (dB), tone accuracy measures how closely the actual emitted wave pattern matches these specified parameters. The closer the emitted wave pattern is to the intended frequency and the intensity, the higher the tone accuracy of the device 100. In an embodiment of the present invention, the output unit 112 of the device 100 may be configured to emit the generated wave pattern with a minimal distortion, unwanted noise, and static in an output produced by the device 100. In a preferred embodiment of the present invention, the distortion faced by the device 100 may be below 1%.
[0059] In an embodiment of the present invention, the display unit 114 may be adapted to display information to the patient regarding an ongoing wave session. The display unit 114 may be located on the front side of the device 100. The information displayed on the display unit 114 may be, but not limited to, a time elapsed, a time remaining, an attempt of the thereby, and so forth. Embodiments of the present invention are intended to include or otherwise cover any information regarding the wave session that may be displayed on the display unit 114, including known, related art, and/or later developed technologies.
[0060] According to embodiments of the present invention, the display unit 114 maybe, but not limited to, a Liquid Crystal Display (LCD), a Light Emitting Diode (LED) display, an Organic Light Emitting Diode (OLED) display, and so forth. Further, the display unit 114 may feature a backlight that may be turned on and/or turned off based on a requirement. Embodiments of the present invention are intended to include or otherwise cover any type of the display unit 114 including known, related art, and/or later developed technologies.
[0061] In an embodiment of the present invention, the battery 116 may be adapted to supply operational power to the components of the device 100. The battery 116 may be a lithium-ion type battery. The battery 116 may provide a backup of 72 hours to the device 100. Further, the battery 116 may be rechargeable and may be recharged using the charging port 118. The battery 116 may be recharged using an input voltage of 5-volts Direct Current (DC) from the charging port 118. In an embodiment of the present invention, the battery 116 may gain a full charge in a time range of 50 minutes to 70 minutes when charged using the input voltage of 5-volts Direct Current (DC) from the charging port 118.
[0062] In a preferred embodiment of the present invention, the charging port 118 may be located on the bottom panel 104b of the device 100. In another embodiment of the present invention, the charging port 118 may be located on the top panel 104a of the device 100. In yet another embodiment of the present invention, the charging port 118 may be located either on the left side panel 104c, or on the right side panel 104d of the device 100. Embodiments of the present invention are intended to include or otherwise cover any location of the charging port 118 on the device 100, including known, related art, and/or later developed technologies.
[0063] FIG. 1C illustrates an exemplary circuit diagram 120 depicting a connection between the processor 110 and the output unit 112 of the device 100, according to an embodiment of the present invention. The exemplary circuit diagram 120 of the device 100 may provide an electrical connectivity between the components of the device 100. The processor 110 may receive input from the input unit 106. Further, the processor 110 may process the received input and may generate and emit the wave pattern using the output unit 112, as explained in the FIG. 1B.
[0064] FIG. 2 illustrates a block diagram of the processor 110 of the device 100, according to an embodiment of the present invention. The processing unit may comprise the computer-executable instructions in form of programming modules such as a data receiving module 200, a data extraction module 202, a data computation module 204, and a wave emission module 206.
[0065] In an embodiment of the present invention, the data receiving module 200 may be configured to receive the inputs of the physical auditory test from the input unit 106 to the storage unit 108. Further, the data receiving module 200 may be configured to receive the inputs related to a size of an ear canal and a middle ear pathway of the patient, in an embodiment of the present invention.
[0066] Upon receipt of the inputs of the physical auditory test from the input unit 106, the data receiving module 200 may be configured to analyze the received inputs of the physical auditory test. The analysis of the physical auditory test may provide a percentage of a Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz), a percentage of a Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz), and a percentage of a Hyperacusis Severity Test (HH1) value at 8 Kilohertz (kHz), and so forth.
[0067] In an embodiment of the present invention, a percentage of a Tinnitus Severity Test (TH1) may involve symptoms such as, but not limited to, concentration issues, sleep disturbance, irritation, anxiety, annoyance, speech interference, and so forth. Embodiments of the present invention are intended to include or otherwise cover any symptoms for calculation of the percentage of the Tinnitus Severity Test (TH1), including known, related art, and/or later developed technologies.
[0068] In an embodiment of the present invention, the percentage of the Hyperacusis Severity Test (HH1) may involve symptoms such as, but not limited to, attention dimension, social, emotional, and so forth. Embodiments of the present invention are intended to include or otherwise cover any symptoms for calculation of the percentage of the Hyperacusis Severity Test (HH1), including known, related art, and/or later developed technologies.
[0069] In an embodiment of the present invention, the percentage of the Dizziness Severity Test (DH1) may involve symptoms such as, but not limited to, total functional effect, total emotional effect, total physical effect, and so forth. Embodiments of the present invention are intended to include or otherwise cover any symptoms for calculation of the percentage of the Dizziness Severity Test (DH1), including known, related art, and/or later developed technologies.
[0070] Upon calculation of the percentage of the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz), the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz), and the percentage of the Hyperacusis Severity Test (HH1) value at 8 Kilohertz (kHz), the data receiving module 200 may transmit the percentage of the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz), the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz), and the percentage of the Hyperacusis Severity Test (HH1) value at 8 Kilohertz (kHz) to the data extraction module 202.
[0071] In an embodiment of the present invention, the data extraction module 202 may be configured to extract a set of variables (s1, s2, and s3) from the analyzed inputs. In another embodiment of the present invention, the data extraction module 202 may be configured to extract the set of variables (s1, s2, and s3) from the percentage of the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz), the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz), and the percentage of the Hyperacusis Severity Test (HH1) value at 8 Kilohertz (kHz).
[0072] Further, the data extraction module 202 may be configured to add the extracted set of variables (s1, s2, and s3) to obtain a total duration (T) of the wave pattern. Upon obtaining the total duration (T) of the wave pattern, the data extraction module 202, may transmit an activation signal to the data computation module 204.
[0073] In an embodiment of the present invention, the data computation module 204 may be activated upon receipt of the activation signal from the data extraction module 202. The data computation module 204 may be configured to compute a first intensity (A), a second intensity (B), and a central frequency (fc) of the wave pattern from the analyzed inputs.
[0074] In an embodiment of the present invention, the first intensity (A) may be a maximum decibel value of 1/10 of 8 Kilohertz (kHz) hearing loss decibel value. The second intensity (B) may be half of the first intensity (A), in an embodiment of the present invention. Further, the data computation module 204 may parse the total duration (T), the first intensity (A), the second intensity (B), and the central frequency (fc) of the wave pattern through an equation for generating the wave pattern. The equation for parsing of the total duration (T), the first intensity (A), the second intensity (B), and the central frequency (fc) of the wave pattern may be denoted using an equation (E1):
[0075] Wave pattern generation = T x A x ?(Sine 2pfc + Cosine 2pfc) + T x B x ?(Sine 2pfc + Cosine 2pfc) --- (E1)
wherein T is the total duration of the wave pattern, A is the first intensity of the wave pattern, B is the second intensity of the wave pattern, fc is the central frequency of the wave pattern.
[0076] In an embodiment of the present invention, after the generation of the wave pattern, the data computation module 204 may be configured to calculate a neuromodulation acoustic energy by multiplying the total duration (T) of the wave pattern with the first intensity (A), and the second intensity (B) of the wave pattern. The neuromodulation acoustic energy may be calculated using an equation (E2):
[0077] Neuromodulation acoustic energy = Total duration (T) x First intensity (A) x Second intensity (B) --- (E2)
[0078] Further, the data computation module 204 may be configured to transmit the generated wave pattern and the calculated neuromodulation acoustic energy to the wave emission module 206.
[0079] In an embodiment of the present invention, the wave emission module 206 may activated upon receipt of the generated wave pattern and the calculated neuromodulation acoustic energy from the data computation module 204. The wave emission module 206 may be configured to actuate the output unit 112 to emit the generated audible wave pattern with the calculated neuromodulation acoustic energy. The audible wave pattern emitted by the output unit 112 may further be carried to the ear(s) of the patient using the listening peripheral. The ear(s) of the patient may receive the emitted wave pattern, and the emitted wave pattern may stimulate and activate dead neurons in a brain of the patient responsible for development of continuous ringing sound in the ear(s) of the patient. As the dead neurons may be activated, the newly activated neurons may enable the patient to hear a corresponding frequency of sounds that were previously inaudible to the patient.
[0080] FIG. 3A illustrates a first graph 300 illustrating a gender based distribution of participants participating in a clinical experimentation for the device 100, according to an embodiment of the present invention. As illustrated in the first graph 300, a total of 46 participants (100%) may have participated in the clinical experimentation for the device 100. Further, as illustrated in the first graph 300, out of the 46 participants, 36 may be a male participating subject (78.3% of the total participants) and 10 may be a female participating subject (21.7% of the total participants).
[0081] FIG. 3B illustrates a second graph 302 illustrating a hearing loss in the right ear of the participants participating in the clinical experimentation for the device 100, according to an embodiment of the present invention.
[0082] As illustrated in the second graph 302, out of a total of a 46 participants, 16 participants (34.8% of the total participants) may have normal right ear hearing. Further, 12 participants (26.1% of the total participants) may have mild hearing loss in the right ear. Moreover, 1 participant (2.2% of the total participants) may have mild conductive hearing loss in the right ear. Furthermore, 1 participant (2.2% of the total participants) may have mild sloping sensorineural hearing loss in the right ear.
[0083] Additionally, as illustrated in the second graph 302, 1 participant (2.2% of the total participants) may have mild sensorineural hearing loss hearing loss in the right ear. Further, 7 participants (15.2% of the total participants) may have minimal hearing loss hearing loss in the right ear. Moreover, 5 participants (10.9% of the total participants) may have moderate hearing loss hearing loss in the right ear. Furthermore, 1 participant (2.2% of the total participants) may have moderate sensorineural hearing loss in the right ear. 2 participants (4.3% of the total participants) may have moderately severe sensorineural hearing loss in the right ear.
[0084] FIG. 3C illustrates a third graph 304 illustrating a hearing loss in the left ear of the participants participating in the clinical experimentation for the device 100, according to an embodiment of the present invention.
[0085] As illustrated in the third graph 304, out of a total of 46 participants, 16 participants (34.8% of the total participants) may have mild hearing loss in the left ear. Further, 7 participants (15.2% of the total participants) may have minimal hearing loss in the left ear. Moreover, 5 participants (10.9% of the total participants) may have moderate hearing loss in the left ear. Furthermore, 3 participants (6.5% of the total participants) may have moderately severe hearing loss in the left ear.
[0086] Additionally, as illustrated in the third graph 304, 13 participants (28.3% of the total participants) may have normal hearing in the left ear. Further, 1 participant (2.2% of the total participants) may have profound hearing loss hearing loss in the left ear. Moreover, 1 participant (2.2% of the total participants) may have severe hearing loss hearing loss in the left ear.
[0087] FIG. 3D illustrates a fourth graph 306 illustrating a mean of ages and improvements in the participants participating in the clinical experimentation for the device 100, according to an embodiment of the present invention. As illustrated in the fourth graph 306, a mean of the ages of a total of 46 participants is 48.65. Additionally, a mean of the improvements of a total of 46 participants is 70.43.
[0088] Further, a youngest participant out of the 46 participants may have an age of 23. An eldest participant out of the 46 participants may have an age of 85. A standard deviation of the ages of the out of the 46 participants may be 15.400. A median of the ages of the 46 participants is 46.
[0089] Furthermore, a minimum improvement observed in a participant out of the 46 participants may be 50. A maximum improvement observed in a participant out of the 46 participants may be 100. A standard deviation of the improvement observed in the 46 participants may be 16.661. A median of the improvement observed in the 46 participants is 75.
[0090] FIG. 3E illustrates a fifth graph 308 illustrating a mean of a Tinnitus Severity Index (THI) in the participants participating in the clinical experimentation for the device 100, according to an embodiment of the present invention. As illustrated in the fourth graph 306, a mean of the Tinnitus Severity Index (THI) of a total of 46 participants before using the device 100 may be 56.96. However, the mean of the Tinnitus Severity Index (THI) of a total of 46 participants after using the device 100 may be 3.54.
[0091] In an embodiment of the present invention, a minimum Tinnitus Severity Index (THI) from the 46 participants before using the device 100 may be 6. The minimum Tinnitus Severity Index (THI) from the 46 participants after using the device 100 may be 0.
[0092] In an embodiment of the present invention, a maximum Tinnitus Severity Index (THI) from the 46 participants before using the device 100 may be 100. The maximum Tinnitus Severity Index (THI) from the 46 participants after using the device 100 may be 16.
[0093] In an embodiment of the present invention, a standard deviation of the Tinnitus Severity Index (THI) of the 46 participants before using the device 100 may be 23.735. The standard deviation of the Tinnitus Severity Index (THI) of the 46 participants after using the device 100 may be 3.278.
[0094] In an embodiment of the present invention, a median of the Tinnitus Severity Index (THI) of the 46 participants before using the device 100 may be 59.00. The median of the Tinnitus Severity Index (THI) of the 46 participants after using the device 100 may be 4.
[0095] In an embodiment of the present invention, a standard score (|Z| value) of the Tinnitus Severity Index (THI) of the 46 participants may be 5.906. A level of marginal significance (p-value) of the Tinnitus Severity Index (THI) of the 46 participants may be 0.000.
[0096] FIG. 3F illustrates a sixth graph 310 illustrating a mean of a Hyperacusis Severity Index (HYP) in the participants participating in the clinical experimentation for the device 100, according to an embodiment of the present invention. As illustrated in the sixth graph 310, a mean of the Hyperacusis Severity Index (HYP) of a total of 46 participants before using the device 100 may be 20.00. However, the mean of the Hyperacusis Severity Index (HYP) of a total of 46 participants after using the device 100 may be 0.07.
[0097] In an embodiment of the present invention, a minimum Hyperacusis Severity Index (HYP) from the 46 participants before using the device 100 may be 0. The minimum Hyperacusis Severity Index (HYP) from the 46 participants after using the device 100 may be 0.
[0098] In an embodiment of the present invention, a maximum Hyperacusis Severity Index (HYP) from the 46 participants before using the device 100 may be 74. The maximum Hyperacusis Severity Index (HYP) from the 46 participants after using the device 100 may be 3.
[0099] In an embodiment of the present invention, a standard deviation of the Hyperacusis Severity Index (HYP) of the 46 participants before using the device 100 may be 17.027. The standard deviation of the Hyperacusis Severity Index (HYP) of the 46 participants after using of the device 100 may be 0.442.
[00100] In an embodiment of the present invention, a median of the Hyperacusis Severity Index (HYP) of the 46 participants before using the device 100 may be 18.00. The median of the Hyperacusis Severity Index (HYP) of the 46 participants after using the device 100 may be 0.
[00101] In an embodiment of the present invention, a standard score (|Z| value) of the Hyperacusis Severity Index (HYP) of the 46 participants may be 5.376. A level of marginal significance (p-value) of the Hyperacusis Severity Index (HYP) of the 46 participants may be 0.000.
[00102] FIG. 3G illustrates a seventh graph 312 illustrating a mean of a Dizziness Severity Index (DHI) in the participants participating in the clinical experimentation for the device 100, according to an embodiment of the present invention. As illustrated in the seventh graph 312, a mean of the Dizziness Severity Index (DHI) of a total of 46 participants before using the device 100 may be 9.87. However, the mean of the Dizziness Severity Index (DHI) of a total of 46 participants after using the device 100 may be 0.35.
[00103] In an embodiment of the present invention, a minimum Dizziness Severity Index (DHI) from the 46 participants before using the device 100 may be 0. The minimum Dizziness Severity Index (DHI) from the 46 participants after using the device 100 may be 0.
[00104] In an embodiment of the present invention, a maximum Dizziness Severity Index (DHI) from the 46 participants before using of the device 100 may be 90. The maximum Dizziness Severity Index (DHI) from the 46 participants after using the device 100 may be 4.
[00105] In an embodiment of the present invention, a standard deviation of the Dizziness Severity Index (DHI) of the 46 participants before using the device 100 may be 19.668. The standard deviation of the Dizziness Severity Index (DHI) of the 46 participants after using of the device 100 may be 0.875.
[00106] In an embodiment of the present invention, a median of the Dizziness Severity Index (DHI) of the 46 participants before using of the device 100 may be 0. The median of the Dizziness Severity Index (DHI) of the 46 participants after using of the device 100 may be 0.
[00107] In an embodiment of the present invention, a standard score (|Z| value) of the Dizziness Severity Index (DHI) of the 46 participants may be 3.658. A level of marginal significance (p-value) of the Dizziness Severity Index (DHI) of the 46 participants may be 0.000.
[00108] In an exemplary scenario, one of the participants from the 46 participants may be a male subject A of 72 years may have a problem with noise irritation. Further, upon conduction of the physical auditory test, the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz) was 34%, the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz) was 0%, and the percentage of the Hyperacusis Severity Test (HH1) was 12%. However, after a year of utilization of the device 100, the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz) came to be 2%, the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz) came to be 0%, and the percentage of the Hyperacusis Severity Test (HH1) came to be 0%. Therefore, an improvement in the tinnitus syndrome of the male subject A over a period of 1 year came to be 100%.
[00109] In another exemplary scenario, one of the participants from the 46 participants may be a female subject B of 46 years may have a problem of vertigo, irritation, and sleeping issues. Further, upon conduction of the physical auditory test, the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz) was 74%, the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz) was 32%, and the percentage of the Hyperacusis Severity Test (HH1) was 14%. However, after a year of utilization of the device 100, the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz) came to be 4%, the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz) came to be 0%, and the percentage of the Hyperacusis Severity Test (HH1) came to be 0%. Therefore, an improvement in the tinnitus syndrome of the female subject B over a period of 1 year came to 90%.
[00110] In another exemplary scenario, one of the participants from the 46 participants may be a male subject C of 40 years may have a problem of vertigo, irritation, and lack of concentration. Further, upon conduction of the physical auditory test, the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz) was 70%, the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz) was 4%, and the percentage of the Hyperacusis Severity Test (HH1) was 43%. However, after a year of utilization of the device 100, the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz) came to be 4%, the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz) came to be 0%, and the percentage of the Hyperacusis Severity Test (HH1) came to be 0%. Therefore, an improvement in the tinnitus syndrome of the male subject C over a period of 1 year came to 80%.
[00111] In another exemplary scenario, one of the participants from the 46 participants may be a female subject D of 49 years may have a problem of head heaviness, noise irritation, concentration issues, and hearing clarity issues. Further, upon conduction of the physical auditory test the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz) was 60%, the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz) was 28%, and the percentage of the Hyperacusis Severity Test (HH1) was 17%. However, after a year of utilization of the device 100, the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz) came to be 16%, the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz) came to be 0%, and the percentage of the Hyperacusis Severity Test (HH1) came to be 3%. Therefore, an improvement in the tinnitus syndrome of the female subject D over a period of 1 year came to 70%.
[00112] In another exemplary scenario, one of the participants from the 46 participants may be a female subject E of 35 years may have a problem of vertigo and head heaviness. Further, upon conduction of the physical auditory test, the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz) was 80%, the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz) was 34%, and the percentage of the Hyperacusis Severity Test (HH1) was 67%. However, after a year of utilization of the device 100, the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz) came to be 16%, the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz) came to be 5%, and the percentage of the Hyperacusis Severity Test (HH1) came to be 3%. Therefore, an improvement in the tinnitus syndrome of the female subject E over a period of 1 year came to 60%.
[00113] In another exemplary scenario, one of the participants from the 46 participants, a male subject F 61 years may have a problem of head heaviness, noise irritation, and sleeping disturbance. Further, upon conduction of the physical auditory test the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz) was 76%, the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz) was 0%, and the percentage of the Hyperacusis Severity Test (HH1) was 23%. However, after a year of utilization of the device 100, the Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz) came to be 8%, the percentage of the Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz) came to be 2%, and the percentage of the Hyperacusis Severity Test (HH1) came to be 0%. Therefore, an improvement in the tinnitus syndrome of the female subject E over a period of 2 years came to 50%.
[00114] FIG. 4 depicts a flowchart of a method 400 for operating the device 100 to manage hearing-related conditions, according to an embodiment of the present invention.
[00115] At step 402, the device 100 may analyze the received inputs of the physical auditory test stored in the storage unit 108.
[00116] At step 404, the device 100 may extract the set of variables (s1, s2, and s3) from the analyzed inputs.
[00117] At step 406, the device 100 may add the extracted set of variables to obtain the total duration (T) of the wave pattern.
[00118] At step 408, the device 100 may compute the first intensity (A), the second intensity (B), and the central frequency (fc) of the wave pattern from the analyzed inputs.
[00119] At step 410, the device 100 may parse the total duration (T), the first intensity (A), the second intensity (B), and the central frequency (fc) of the wave pattern through the equation for generating the wave pattern.
[00120] At step 412, the device 100 may calculate the neuromodulation acoustic energy by multiplying the total duration (T) of the wave pattern with the first intensity (A), and the second intensity (B) of the wave pattern.
[00121] At step 414, the device 100 may actuate the output unit 112 to emit the audible wave pattern with the calculated neuromodulation acoustic energy.
[00122] While the invention has been described in connection with what is presently considered to be the most practical and various embodiments, it is to be understood that the invention is not to be limited to the disclosed embodiments, but on the contrary, is intended to cover various modifications and equivalent arrangements included within the scope of the appended claims.
[00123] This written description uses examples to disclose the invention, including the best mode, and also to enable any person skilled in the art to practice the invention, including making and using any devices or systems and performing any incorporated methods. The patentable scope of the invention is defined in the claims and may include other examples that occur to those skilled in the art. Such other examples are intended to be within the scope of the claims if they have structural elements that do not differ from the literal language of the claims, or if they include equivalent structural elements within substantial differences from the literal languages of the claims.

, Claims:CLAIMS
I/We Claim:
1. A neuromodulation device (100), the device (100) comprising:
an input unit (106) adapted to receive inputs from a physical auditory test conducted on a patient;
a storage unit (108) adapted to store the received inputs; and
a processor (110) connected to the storage unit (108), characterized in that the processor (110) is configured to:
analyze the received inputs of the physical auditory test stored in the storage unit (108), wherein the analysis of the received inputs provides a percentage of a Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz), a percentage of a Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz), and a percentage of a Hyperacusis Severity Test (HH1) value at 8 Kilohertz (kHz), or a combination thereof;
extract a set of variables (s1, s2, and s3) from the analyzed inputs;
calculate a total duration (T) of a wave pattern by summing the extracted set of variables (s1, s2, and s3);
compute a first intensity (A), a second intensity (B), and a central frequency (fc) of the wave pattern from the analyzed inputs;
parse the total duration (T), the first intensity (A), the second intensity (B), and the central frequency (fc) of the wave pattern through an equation (E1) for generating an audible wave pattern;
calculate a neuromodulation acoustic energy by multiplying the total duration (T) of the wave pattern with the first intensity (A), and the second intensity (B) of the wave pattern; and
actuate an output unit (112) to emit the generated audible wave pattern with the calculated neuromodulation acoustic energy.
2. The device (100) as claimed in claim 1, wherein the processor (110) is configured to receive the inputs related to a size of an ear canal and middle ear pathway of the patient.
3. The device (100) as claimed in claim 1, wherein the generated wave pattern emitted from the output unit (112) comprises a sine component of the wave pattern, a cosine component of the wave pattern, or a combination thereof.
4. The device (100) as claimed in claim 1, wherein the processor (110) is configured to store the generated wave pattern in the storage unit (108).
5. The device (100) as claimed in claim 1, wherein the input unit (106) is a membrane keypad.
6. The device (100) as claimed in claim 1, wherein the output unit (112) is configured to enable the patient to receive the generated wave pattern stored in the storage unit (108).
7. The device (100) as claimed in claim 1, wherein the output unit (112) is selected from a mono channel, a stereo channel, or a combination thereof.
8. The device (100) as claimed in claim 1, comprising a display unit (114) adapted to display information to the patient regarding an ongoing wave session.
9. A method (400) for operating a neuromodulation device (100) to manage hearing-related conditions, the method (400) is characterized by steps of:
analyzing received inputs of a physical auditory test stored in a storage unit (108), wherein the analysis of the received inputs provides a percentage of a Tinnitus Severity Test (TH1) value at 8 Kilohertz (kHz), a percentage of a Dizziness Severity Test (DH1) value at 8 Kilohertz (kHz), and a percentage of a Hyperacusis Severity Test (HH1) value at 8 Kilohertz (kHz), or a combination thereof;
extracting a set of variables (s1, s2, and s3) from the analyzed inputs;
calculating a total duration (T) of a wave pattern by summing the extracted set of variables (s1, s2, and s3);
computing a first intensity (A), a second intensity (B), and a central frequency (fc) of the wave pattern from the analyzed inputs;
parsing the total duration (T), the first intensity (A), the second intensity (B), and the central frequency (fc) of the wave pattern through an equation (E1) for generating an audible wave pattern;
calculating a neuromodulation acoustic energy by multiplying the total duration (T) of the wave pattern with the first intensity (A), and the second intensity (B) of the wave pattern; and
actuating an output unit (112) to emit the generated audible wave pattern with the calculated neuromodulation acoustic energy.
10. The method (400) as claimed in claim 9, wherein the wave pattern emitted from the output unit (112) is selected from a sine component of the wave pattern, a cosine component of the wave pattern, or a combination thereof.
Date: 30 September 2024
Place: Noida
(Dr. Keerti Gupta)
Agent for the Applicant
(IN/PA-1529)